Adenoviral vectors comprising partial deletions of E3
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
Apr 18, 2017
Issued Date -
N/A
app pub date -
Feb 26, 2014
filing date -
Mar 1, 2013
priority date (Note) -
In Force
status (Latency Note)
Importance
Abstract
This disclosure provides replication-incompetent adenoviral vectors useful in vaccine development and gene therapy. The disclosed vectors comprise a selective deletion of E3 and are particularly useful for preparation of vaccines development and for gene therapy using toxic transgene products that result in vector instability that occurs when the entire E3 domain is deleted.
First Claim
Family
International Classification(s)
Cited Art Landscape
Patent Citation Ranking
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully